Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Biotech investing surges
http://www.bostonglobe.com/business/2013/10/17/venture-spending-slightly-rise-biotech-funding/FldKxwZRCEqF2Y7VeAdxsN/story.html
Buoyed by a rising stock market and the successful debut of several public companies, investors poured more than a quarter-billion dollars into biotech start-ups in the Boston area during the third quarter of this year.
The surge in investments — worth $266 million — is an abrupt turnaround from the previous quarter, when the biotechnology sector experienced its lowest level of funding in nearly a decade, according to the MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association, based on data from Thompson Reuters.
That poor showing was immediately followed by highly successful initial public offerings of Boston-area biotechs.
For example, Foundation Medicine Inc. was launched in late September at $18 a share and raised $106 million. On Thursday, those shares closed at $34.88.
Related
Graphic: More cash for venture capital
That successful debut followed several other Massachusetts biotechnology IPOs, including by Enanta Pharmaceuticals Inc., Bluebird Bio Inc., and Agios Pharmaceuticals Inc. — all of which seems to have piqued investors’ interest in drug makers.
‘Right now, biotech is booming. There’s renewed interest.’
“Right now, biotech is booming. There’s renewed interest,” said Jeff Fagnan, a partner at the Cambridge firm Atlas Venture, which invests in life science and software start-ups.
The rebound helps reinforce the area’s reputation as a hub for medical and pharmaceutical innovation, and it comes at a time of increased overall activity in the venture market, said Fagnan, whose firm invested in a handful of biotech start-ups in the last quarter.
Overall, Atlas was the most active local venture firm during the period, according to the report from MoneyTree, and invested in about 25 start-ups over the quarter. Of the companies that Atlas invested in for the first time, the vast majority are in Boston.
“We are maniacally focused on Boston,” Fagnan said. “It’s a great time for entrepreneurship and innovation.”
Atlas, however, was not in on the largest deal of the quarter: $60 million to Dicerna Pharmaceuticals Inc., an early-stage company in Watertown that is working on advanced therapeutic treatments for cancer and other diseases.
Beyond biotech, total venture spending in New England for the third quarter rose 7 percent to a total of $870 million; nationally, such investments climbed about 11 percent to $7.7 billion.
The overall rise in venture spending follows recent growth in the stock market as well as a spate of technology stock offerings that have scored well with public investors, said Neeraj Agrawal, a general partner at Battery Ventures in Waltham, another one of the area’s most active firms during the quarter.
“It’s frothy out there,” said Agrawal. “We’re in a very nice bull market, and it’s benefiting venture capital.”
His firm invested in four new companies, while several of the older firms in its portfolio were acquired or went public, giving Battery a windfall valued around $500 million.
Most of Battery’s recent investments have been in the software market, which had also hit a lull last quarter.
Nationally, investments in software start-ups hit $3.56 billion, a level not seen since the booming Internet days of early last decade. Locally, the sector accounted for the greatest number of deals for the period, with 32 investments.
Only one Boston-area software firm, the mobile payment firm Paydiant Inc. of Wellesley made it onto the MoneyTree list of the 10 biggest regional deals. It raised $20.5 million.
The dollar amount going into software start-ups is falling because it take less money to get those companies off the ground, compared with the capital-intensive biotechnology and medical device companies, according to investors.
“You see a lot of companies that are able to start on a few million dollars,” said Fagnan, from Atlas. “My sense is that the average investment size is going to continue going down.”
Our little company is not yet known.
Large investors focus on big deals!
Wait to see when our little company will surpass everyone of the big pharmaceutical biotech companies where "The AMEX investors" usually invest their money on.
Remember my little story about the snail.
FN
Have some body with you when your alarm is going to ring!
You might be shocked!
FN
Let the battle begin!
I knew it!
I woke up early to read the great news
This is going to be an amazing day!
FN
Cannot wait !!
Thanks for your wishes Weedie!
2014 is going to be very important for NNVC !
Are you ready?
They don't celebrate Thanksgiving !
There result might be very soon !
FN
Yes, December should be a good month!
FN
And that is why we are in goods hands!
FN
Better being positive than negative!
I wish to all the board and NNVC team
A BIG "Happy thanks giving"
FN
I hear you. A work of this magnitude takes a long time.
And this is normal.
It take 5 years for a normal business to succeed.
So imagine a biotech company who has a product that will change the course of medicine!
For me, I'm surprised that they move so quickly.
FN
And they will blame Dr Seymour for that!
another_voice_2
We had a similar post!
I'm curious to see what some people on this board will find to complain about when NNVC will be at $500!
Look at the positive sides from Dr Seymour's and Dr Diwan hards work:
Successful results on animal testing where other big companies did not .
Receiving Orphan Drug Designation From the European Medicines.
Bringing FluCide to the FDA.
Building a clinical facility in Shelton for human testing.
Be part of the world’s most important capital markets!
And yet you continued to complain and criticize.
Can you recognize the efforts that Dr. Seymour is actually doing to bring NNVC's drugs into the world?
I know you're here for your wallet.
I am here to support this company and I am very lucky and grateful to be part of NNVC.
FN
It is difficult to reason with people who always want to be right.
New news is what we need. Hopefully on Monday.
I just red your last post!
In my turn I am returning the compliment:
Your comments are so smart that you made a lot of fans on that board.
Well done!
FN
That message was of course for David! My cell is making jokes to me!
Or you can use the iggy button !!
That idea has been recommended by thedane and it works very well !
I don't see his posts and I don't think that he sees mines !
Well, what can we do?
Two days ago, after an attack to Dr. Seymour I replied.
And I received another warning from the IH Admin.
I was in the process of defending Dr. Seymour about his attacks that have no meaning.
Oh well!
oops Wrong dates! Sorry!
I went to the start of their shares!
It looks like ALR was at:
30.04 on Sept 10
39.46 on Jan 14
40.10 on Feb 11
From our friends ''goog"
An apology to Dr Seymour!
OVIDIUS
Ho my Gods! So much evidence!
OOOOHHHH! That's must hurt!
Sorry Ovidius !
Have a nice day!
FN
I still love that video!
It's says everything with no words.
FN
We are in good hands:
http://investing.businessweek.com/research/stocks/people/person.asp?personId=22688191&ticker=NNVC
Eugene Seymour M.D., MPH
Chief Executive Officer and Director, NanoViricides, Inc.
Age
Total Calculated Compensation
This person is connected to 8 board members in 1 different organizations across 1 different industries.
See Board Relationships
73
$462,387
As of Fiscal Year 2013
Background*
Dr. Eugene Seymour, M.D., MPH, has been the Chief Executive Officer of NanoViricides, Inc. since June 8, 2005. Dr. Seymour served as the Chief Financial Officer of NanoViricides, Inc. since June 8, 2005 and also served as its Principal Accounting Officer. Dr. Seymour served as an Interim Chief Financial Officer of NanoViricides, Inc. since May 16, 2007. He began clinical practice in Internal Medicine and joined the UCLA Medical School faculty. He Left UCLA after two years and joined USC faculty as Associate Professor. He served in the Medical Corps of United States Army Reserve during the Vietnam era and attained the rank of Major. He was originally trained as a chemist, but decided to attend medical school in preparation for a career as a clinical investigator. In 1981, Dr. Seymour began treating patients with a strange new disease affecting primarily the gay population. He worked with a number of celebrity patients whose identity could not be disclosed for fear of being ostracized in the entertainment community. In 1986, he was requested by the United States government to establish a testing laboratory and run a large-scale surveillance program for HIV prevalence in the Hispanic population in Los Angeles. In 1989, he founded Saliva Diagnostic Systems Inc.and served as its Chief Executive Officer and President since 1993. He left SDS in 1996 to form a non-profit foundation, which funded both testing and training programs for health workers in Asia and Africa. Dr. Seymour served as a Consultant to the United Nations Global Program on AIDS and was sent to a number of different countries, (Lithuania, Latvia, Estonia, and Russia) to interact with local physicians and assist them in setting up testing programs. He served as the Chairman of NanoViricides, Inc. since June 8, 2005 and has been its Director since June 1, 2005. He served as a Director of Strategic Alliances at a medical education startup called Medschool.com. Dr. Seymour spends his time as a private investor evaluating evolving companies in the field of biotechnology. He is the holder of 8 issued patents. Following postgraduate medical training, he holds a Master's degree in the Epidemiology of Infectious Diseases at UCLA.
Collapse Detail
What's Being Told and proving something are very different.
You did not respond to my question.
Can you advance evidence on your charges to Dr. Seymour?
Can you give us proof?
Investors are focusing on tech stock Today!
Included NNVC.
FN
Yes! Hopefully it's going to stay that way today!
Dr Seymour response:
I'm going there on the 9th
We're going to post pictures and maybe a video on the new website after the meeting.
You're going to love the new presentation
Sent from my iPhone
Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
eugene@nanoviricides.com
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange
It's shipper !
And my customers at NORDSTROM are complaining because everything is make in China!
Thanks for the info!
I love that video from my wife's cousin NORRIS!
I agree with you! He might be very good!
Nothing wrong with exploring.
FN
This is all very simple PR that can be easily addressed with site photos, interviews with the construction folks etc...and then posting that message on the website. I'd be happy to do it if NNVC would hire someone to do PR